Iconovo kommer under kvartalet att delta på följande events och där presentera bolaget.

Aktiespararna – Aktiedagen Lund

Presentation Iconovo Onsdag 27 januari kl. 10.15-10.45

Datum: 27 och 28 januari 2021
Tid: 08.00-21.00
Plats: Digital, livestreaming via webb

Anmälningar via Hemsida/website: https://www.aktiespararna.se/aktiviteter/aktiedagen-lund-digitalt
Vi streamar live och on demand via Aktiespararnas YouTube-kanal samt via aktiespararna.se

Swiss Nordic Bio

Datum: 10 och 11 februari 2021
Tid: 09.00-18.00
Plats: Digital, livestreaming via webb


Stockholm Corporate Finance 13:e Life Science-seminarium 

Stockholm Corporate Finance bjuder in investerare, analytiker och finansmedia till det trettonde årliga Life Science-seminariumet i samarbete med Financial Hearings. Moderator under dagarna är Charlotte Stjerngren, partner Cord Communications.

Datum: 23 och 24 mars 2021
Tid: 07.30-12.15
Plats: Digital, livestreaming via webb

Klicka på nedanstående länk för att anmäla dig till seminariumet.
Anmälning via: https://www.lyyti.fi/reg/scf-life-science-seminarium-2021

Lund, December 21, 2020. Iconovo AB (publ) today announced that the company has signed a development agreement with Monash University for the development of inhaled oxytocin in ICOone®. The agreement verifies the suitability of ICOone for use with innovative pharmaceuticals. Monash University’s Institute of Pharmaceutical Sciences (MIPS) is leading the development project supported by a research agreement with Janssen Pharmaceutica N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and ongoing support from long term partner GSK.

The agreement gives Monash an exclusive global right to use ICOone with oxytocin to prevent postpartum haemorrhage in women giving birth. The agreement has a staged technology access fee of €900,000 that will be triggered by milestones in the clinical trial stage of the project where the first out of three milestones will be paid as an exercise fee to license the device subject to a positive Phase 1 trial that is planned for 2021. In addition, Monash will pay Iconovo for commissioned development work through milestones that are yet to be defined. Royalties from sales over a 20-year period from launch will be in the 5 – 10 % range, as previously communicated for similar agreements.

“We are excited to be contributing with ICOone and our inhalation know-how to such an important medical innovation. There is a huge need to ease administration of oxytocin so that these unnecessary and tragic deaths can be reduced all over the globe. In this project, we all come together to make great things happen,” said Johan Wäborg, CEO of Iconovo.

“For Iconovo, this project will broaden our experience to include innovative development and we look forward to many more such projects where we can use our inhalation experience. It sends a clear signal that these innovation-focused partners see ICOone as a promising inhaler for innovative applications. We are very pleased that we now have commercial royalty bearing agreements for all Iconovo’s three platforms,” continued Johan Wäborg.

Currently, injectable oxytocin is used to prevent postpartum hemorrhage (PPH) after childbirth. It is recommended by the WHO that women should receive an injected dose of oxytocin during the third stage of labor to prevent PPH. An inhaled formulation can provide important advantages such as ease of use, cheaper transport and storage without cold chain and no handling of used needles and syringes. It is particularly important in parts of the world where infrastructure is less developed, like in rural parts of Africa or Asia. To remove the need for a cold-chain and the management of hazardous waste will be a great cost reduction and potentially help eliminate disease spreading by infected needles. Iconovo estimates that there are 115 million live births in the region of interest, whereof 65 million are in rural areas with the greatest need. Iconovo believes that the product will be used in 15 – 20 % of live births in rural areas. In the future there is a possibility that also other markets like USA and Europe will open for inhaled oxytocin as a safer, non-invasivealternative to injections.

“This is an exciting opportunity to expand this collaboration between industry and academia to develop an important healthcare innovation that aims to address a critical unmet medical need,” said Monash University’s Professor Michelle McIntosh, who has pioneered the inhaled delivery of oxytocin. “There is a massive ripple effect when a mother dies – it's a very significant burden for these families and communities, and we are committed to bringing gold-standard care to all mothers.”

ICOone is a single-dose inhaler designed for ultra-low manufacturing cost and easy operation. In these areas, ICOone is particularly suitable since it can deliver one dose at a low price-point and with a mode of operation that requires a minimum of training. Therefore, ICOone supports the potential of delivering an inhaled oxytocin product at an affordable price point comparable to other uterotonic options available in low- and middle-income countries.

About PPH
PPH, a condition of excessive blood loss after birth, is the leading cause of maternal mortality globally, resulting in an estimated 60,000 deaths per year, overwhelmingly in resource-limited countries. Most deaths resulting from PPH could be avoided if access to suitable medical innovation were available. It is effectively managed in developed countries using the gold standard therapy, oxytocin, a manufactured form of a natural hormone. Accessibility to quality oxytocin in resource-poor countries is, however, limited as current products are only available in an injectable form requiring supply and storage under refrigerated conditions and trained personnel to administer the product safely.

About ICOone®
ICOone is a unique, patented dry powder inhaler for single use. The smart design generates an ultra-low manufacturing cost combined with simple and discreet use. It is particularly suitable for short-term treatment and as-needed use as it provides an unsurpassed low treatment cost and price point for treatments with a low number of doses. The simple design also enables patients and caregivers to learn how to handle the inhalers with minimal training. ICOone can deliver large inhalation doses that are well protected against moisture, an important factor for many biomolecules.

About Monash University’s Institute of Pharmaceutical Sciences (MIPS)
MIPS has formed an alliance with a number of industry partners, including Janssen Pharmaceutica N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and GSK, as well as philanthropic organisations such as the McCall MacBain Foundation, to develop a novel, temperature-stable formulation of oxytocin. The 2020 QS World University Rankings by Subject ranked Monash University number two in the world for Pharmacy and Pharmacology. The University has also retained a long-held position as Australia’s and the Asia-Pacific’s number one University for Pharmacy and Pharmacology, and since the subject rankings were introduced in 2011 has consistently ranked in the most elite group of Pharmacy and Pharmacology programs worldwide with an average top ten ranking.

For further information, please visit https://www.monash.edu/pharm/research/pharmaceutical-sciences.

Lund, 21 december, 2020. Iconovo AB (publ) meddelar i dag att bolaget har tecknat ett avtal med Monash University för utveckling av inhalerat oxytocin i ICOone®. Avtalet bekräftar lämpligheten att använda ICOone för innovativa läkemedelsprojekt. Monash University Institute of Pharmaceutical Sciences (MIPS) leder utvecklingsprojektet i ett forskningssamarbete med Janssen Pharmaceutica N.V., del av Janssen Pharmaceutical Companies inom Johnson & Johnson, med löpande stöd från långtida partnern GSK.

Avtalet ger Monash University en exklusiv global rättighet att använda ICOone med oxytocin för att förebygga blödning postpartum hos födande kvinnor. Avtalet har stegvisa betalningar av en s.k. technology access fee på €900,000 som kommer att betalas i tre olika milstolpar under den kliniska utvecklingen, där den första milstolpen kommer betalas som en licensavgift för projektet efter en positiv fas 1 studie som är planerad till 2021. Monash kommer också att betala Iconovo för stödjande utvecklingsarbete i projektet genom ytterligare betalningar som ännu inte har avtalats. Avtalet ger royalties över en 20-årsperiod från lansering som kommer att ligga i intervallet 5 – 10 %, vilket är samma som tidigare kommunicerats för liknande avtal.

“Vi är väldigt glada att kunna bidra med ICOone och vårt inhalationskunnande till en otroligt viktig ny medicinsk innovation. Det finns ett stort behov av att förenkla administrationen av oxytocin så att dessa onödiga och tragiska dödsfall kan reduceras i hela världen. I detta projekt går vi alla samman för att få viktiga saker att verkligen hända” säger Johan Wäborg, VD på Iconovo.

“Det här projektet innebär att Iconovo breddar erfarenheten till innovativa utvecklingsprojekt och vi ser fram emot att jobba med fler liknande projekt där vi kan bidra med vår erfarenhet inom inhalation. Det skickar en stark signal till marknaden att dessa innovations-fokuserade spelare ser ICOone som en passande inhalator för innovativa applikationer. Vi är mycket glada att vi nu har kommersiella royaltyavtal för tre inhalationsplattformar från Iconovo” fortsätter Johan Wäborg.

I dag används injicerat oxytocin för att förhindra blödning postpartum (eng: postpartum hemorrhage PPH) efter barnfödsel. WHO rekommenderar att kvinnor bör få en injicerad dos av oxytocin under det tredje stadiet av förlossningen för att förhindra PPH. En inhalerad beredning ger viktiga fördelar såsom en lättare användning, billigare transporter, lagring utan krav på kylskåpstemperatur och ingen hantering av nålar och sprutor. Det är speciellt viktigt i delar av världen där infrastrukturen är mindre utvecklad, som på landsbygden i Afrika och Asien. Att avlägsna behovet av kylskåpstemperatur och hantering av smittosamt avfall ger en stor kostnadsbesparing och kan potentiellt eliminera risken för sjukdomspridning genom infekterade nålar. Iconovo estimerar att det sker 115 miljoner födslar i det aktuella området per år varav 65 miljoner är på landsbygden där behovet är som störst. Iconovo tror att produkten kan komma att användas vid 15 – 20 % av födslarna på landsbygden. I framtiden finns det även en möjlighet att marknader som Europa och USA kommer öppna upp för inhalerat oxytocin som ett säkrare non-invasivt alternativ till injektioner.

“Det här är en spännande möjlighet att öka samarbetet mellan industrin och den akademiska världen för att utveckla viktiga innovationer inom sjukvården för att lösa angelägna medicinska behov” säger Professor Michelle McIntosh vid Monash University som har varit en pionjär i utvecklingen av inhalerat oxytocin. “Det ger stora ringar på vattnet när en mamma dör – det är en tung börda för både familjen och samhället och vi har tagit på oss ett ansvar för att ge dessa gravida kvinnor tillgång till den bästa behandlingen.”

ICOone är en engångsinhalator designad för en ultra-låg tillverkningskostnad och enkel användning. Inom detta behandlingsområdet är ICOone speciellt lämplig eftersom den kan leverera en inhalerad dos till ett lågt pris och med ett enkelt användningssätt som kräver minimal instruktion. ICOone stödjer därför ambitionen att utveckla ett inhalerat oxytocin till ett rimligt pris jämfört med andra uteruskontrakterande alternativ i låg- och medelinkomst-länder.

Om Blödning postpartum (eng: postpartum hemorrhage PPH)
Blödning postpartum är ett tillstånd av excessiv blödning efter förlossning, är den vanligaste orsaken till mödradödlighet globalt, beräknas orsaka 60 000 dödsfall per år och majoriteten sker i resursbegränsade länder. De flesta dödsfall i blödningar efter förlossning skulle kunna undvikas om lämplig medicinsk behandling fanns tillgänglig. Det behandlas effektivt i resurs-starkare länder genom att använda bästa tillgängliga terapi som är oxitocin, en tillverkad form av ett naturligt hormon. Tillgängligheten till högkvalitativt oxytocin är i dag begränsad i resurssvaga länder av att endast injicerbart oxytocin finns tillgängligt som kräver transport och förvaring i kylskåpstemperatur och utbildad personal för att ge produkten på ett säkert sätt.

Om ICOone®
ICOone är en unik och patenterad torrpulverinhalator avsedd för engångsbruk. Den smarta konstruktionen ger en ultralåg tillverkningskostnad kombinerad med en enkel och diskret användning. Den är speciellt lämplig för korttidsbehandlingar och sällandoserings-behandlingar då den ger en oöverträffat låg behandlingskostnad och prispunkt för behandlingar med få doser. Den enkla konstruktionen gör också att patienter och behandlare kan lära sig hantera inhalatorn med minimal träning. ICOone kan leverera stora inhalationsdoser som är väl fuktskyddade, vilket är viktigt för många biomolekyler.

Om Monash University Institute of Pharmaceutical Sciences (MIPS)
MIPS har bildat en allians med ett antal industriella partnerföretag, inklusive Janssen Pharmaceutica N.V., del av Janssen Pharmaceutical Companies i Johnson & Johnson gruppen, och GSK, såväl som filantropiska organisationer såsom McCall MacBain Stiftelsen, för att utveckla nya temperaturstabila formuleringar av oxytocin. 2020 QS World University Rankings by Subject rankade Monash University som nummer två i världen inom Farmaci och Farmakologi. Universitetet har länge hållit en position som Australiens och Asien-Stillahavsområdets främsta universitet inom farmaci och farmakologi, och sedan ranking systemet introducerades 2011 har universitetet konsekvent rankats i elitgruppen inom farmaci och farmakologi globalt med en genomsnittlig topp-10 rankning.

För mer information, besök

Iconovo meddelar att en typ III Drug Master File (DMF) för ICOcap® har skickats in till amerikanska läkemedelsmyndigheten FDA av bolagets partner Stevanato. ICOcap® har utvecklats av Iconovo. Nya ICOcap® kunder kan referera till denna DMF ansökan när de skickar in registreringsansökan av en drug-device produkt för USA-marknaden. Denna FDA ansökan följer på en tidigare CE-märkning för kliniska prövningar i EU för ICOcap®.

”Stevanato gör ett fantastiskt arbete i förberedelserna för att få ICOcap® lanserad globalt av läkemedelsföretag som vill använda ICOcap® i sina inhalationsprodukter. De har nu tagit rejäla kliv framåt på två av de viktigaste marknaderna i världen. USA, som är världens största läkemedelsmarknad, är en avgörande marknad för framgång med ICOcap®”, säger Johan Wäborg, VD på Iconovo.

Om ICOcap®

ICOcap® är en robust kapselinhalator med en unik greppvänlig design, ett patenterat integrerat lock som gör den lätt att använda. ICOcap® är designad med ett lågt inhalationsmotstånd men kan anpassas till önskat inhalationsmotstånd. ICOcap® är direkt tillgänglig från Stevanato för snabb produktlansering och konkurrenskraftigt pris.

Iconovo announce that the capsule-based dry powder inhaler ICOcap® has been submitted to U.S. Food and Drug Administration (FDA) by partner Stevanato as Type III Drug Master File. New customers to ICOcap® can now reference this DMF submission when developing their drug-device product for the US market. This FDA submission follows a receival of CE-mark in European Union for clinical trials with ICOcap®.

”Stevanato is doing a great job in getting the ICOcap® inhaler globally ready for pharmaceutical companies to develop their products with ICOcap®. Now they have managed to take major steps in two of the largest markets in the world. US, the largest pharma market in the world, is a crucial market to be in with ICOcap®”, says Johan Wäborg, CEO for Iconovo.

About ICOcap

ICOcap is a patented capsule-based dry powder inhaler with a one-piece-design and improved handling features making it easy-to-use. It is currently designed with a low flow resistance but can be customized to a flow resistance of choice. ICOcap™ is available from Stevanato for quick product launch and competitively priced off-the-shelf supply.

Good progress in customer projects

Key figures in TSEK unless otherwise indicated  Jul-Sep 2020 Jul-Sep 2019 Jan-Sep 2020 Jan-Sep 2019 Jan-Dec 2019
Net turnover 5,754 3,474 10,111 11,737 11,737
Operating profit/loss -2,304 -2,036 -13,104 -4,567 -11,774
Cash flow for the period -3,640 -4,908 -17,069 -12,299 36,106
Earnings per share (SEK) before full dilution -0.25 -0.26 -1.62 -0.57 -1.68
Cash and cash equivalents 72,087 40,751 72,087 40,751 89,156
Equity 97,245 60,125 97,245 60,125 108,794
Number of shares at period-end 7,776,000 6,776,000 7,776,000 6,776,000 7,776,000
Number of royalty agreements** 4 3 4 3 3

**Number of agreements at the end of the period.

Significant events 1 July – 30 September

  • Iconovo has signed a regional know-how licensing agreement with BNC Korea Co Ltd. The agreement gives exclusive rights to manufacture, market, sell and distribute two capsule formulations together with ICOcap in the territory. The deal has a milestone value of TEUR 550 and additional future royalties of a medium single-digit percentage of sales.
  • The United States Patent and Trademark Office issued an intention to approve (Notice of Allowance) a patent for the ICOres inhalation platform.

Significant events 1 January – 30 June

  • Amneal joined as a new partner in the development of Iconovo’s project with generic Symbicort. Amneal is taking over all obligations under the current agreement from CBC. The project will proceed according to plan.
  • The ICOcap capsule inhaler has become CE-marked for use in clinical trials and can be purchased directly from Stevanato, which is the manufacturing and distribution partner.
  • Iconovo only anticipates a limited impact from COVID-19 currently and in the future. The company has the required goods in stock, and sales are not physical. The greatest potential impact would be some delay in development in the event that company employees fall ill.
  • Gunnar Gårdemyr was elected to the Board at the Annual General Meeting. Gunnar has a degree in economics from Lund University and over 35 years of experience in the pharmaceutical and biotech industry. Previous positions include CEO of Targovax AS, SVP Commercial development/M&A at Nycomed, Global marketing director at Ferring.
  • Orest Lastow took the role of company Chief Technology Officer (CTO), and Johan Wäborg was hired as the new CEO of Iconovo in April. Orest Lastow, one of the co-founders, is one of the largest shareholders together with the company’s Chairman of the Board. Orest previously combined the position of CEO and CTO. He will now devote all of his time to the role of company CTO. Orest is the inventor behind Iconovo’s three inhaler platforms and will now focus on the development of the new ICOpre platform.
  • On 11 March 2020, an Extraordinary General Meeting was held which decided on an incentive programme and the issue of 200,000 warrants to the future CEO. Subsequently, there was subscription of 200,000 warrants for a total of SEK 1,224,000.
  • The Chinese Patent Office issued an Intention to Grant notification regarding a patent for the ICOres inhalation platform. The European Patent Office, EPO, issued an Intention to Grant notification for the third European patent for the ICOres inhalation platform (which is already covered by three approved Swedish patents, two European patents, and one Japanese patent). The patents describe the technology used in Iconovo’s many customer projects, including generic Symbicort.
  • The European Patent Office, EPO, issued an Intention to Grant notification for the first European patent for the ICOone inhalation platform (which is already covered by two approved Swedish patents). The patent describes the technology used in Iconovo’s vaccine project.

Significant events after the end of the third quarter

  • Iconovo recruited a Director Project Management and a Director Alliance Management. These roles will focus on customer needs and enable the delivery of high-quality customer projects in a planned, efficient manner.

A word from the CEO

Strongest quarter in three years
During the third quarter, significant progress was made in the projects, and several milestones were achieved and could be invoiced to Amneal and Intas. Sales for the quarter amount to SEK 5.8 million, making it the strongest quarter in three years.

Generic Symbicort
The Amneal project with a generic version of Symbicort in ICOres is now in its final phase and work with the final milestones will take place in the next quarter. The final technical delivery will then take place at the beginning of next year and the customer will begin pharmacokinetic studies. The purpose of the studies is to verify that our product gives the patient the same uptake of drug as the original product.

With the technical delivery completed at the beginning of next year and an assumption that the studies will be positive, we can assume that launch in European countries should be possible from early to mid-2023. This timepoint will also mark the start of royalty income for Iconovo from this product.

Important new agreement
In early July, we were able to announce a new customer agreement with BNC Korea. In connection with signing, a technology access fee of EUR 150 000 was paid. The agreement relates to the development of generic formulations of Seebri and Ultibro, which will be used in our ICOcap inhaler.

It is an important agreement for several reasons. Having active customers and business in Asia will help us establish more projects in this part of the world. The contracted territory currently has about 2.7 billion inhabitants, and they are increasing sharply in both number and purchasing power. In the near future, this part of the world may drastically increase its need and consumption of inhalation drugs. The territory currently accounts for approximately 15% of global Seebri and Ultibro sales, which means that the remaining 85% is left as an opportunity for a new contract.

The agreement also serves as verification that a model with early in-house development of certain interesting formulations makes our projects even more commercially viable. Since this leads to a more finished product, it will also be easier for the customer to enter into an agreement.

Other progress during Q3
Our ICOres project with Intas also made good progress in Q3, with subsequent invoicing of milestones. The Intas project will enter a new phase at the beginning of next year, when a period of technical delivery begins. We expect the entire project to be fully delivered by the end of 2022.

COVID-19 has had minimal impact on Iconovo and the work with our projects is progressing according to plan. In business development, it is also possible to maintain a high level of activity through virtual meetings. We look forward to and are planning to reconnect with our customers via physical meetings as soon as possible.

Investments for increased capacity and customer focus
We have recently made many investments that will help us expand our capacity, put further focus on project implementation, and make us even better in attracting new customers.

During the period July-October, we appointed four new highly qualified people: a formulation specialist, a mechanical design engineer, a personal responsible for commercial partnerships and customer relationships, and a senior project manager.

We are also building efficiency and capacity through several investments, including adaptation of the quality system to meet the requirements of the US Food and Drug Administration (FDA), acquisition of modern HPLC equipment, and setup of two new formulation labs. The new labs will lead to higher capacity and efficiency. At the same time, several patents, design protection and trademarks have also been registered. Last, but not least, we are making investments in the development of the new ICOpre platform according to plan.

I consider the investments we are now making, absolutely necessary in order to help the company grow, keep up our pace, and increase our commercial success.

Our investments affect our cash flow, but at the same time are balanced by good invoicing. We are currently well capitalised and had SEK 72 million in cash and cash equivalents at the end of September. At our current burn rate, our capital is estimated to last just over 3 years. This takes us into a period when we are expected to receive royalties, which will provide good profitability in the company.

Optimistic about next quarter
We are now keeping the same high pace in our delivery of current milestones for the rest of the year. We therefore expect to be able to invoice to the same extent in Q4 as we were in Q3.

Johan Wäborg, CEO

Iconovo meddelar att man genomfört två nyrekryteringar för att fokusera på kundernas behov och för att kunna leverera kundprojekt på ett planenligt effektivt sätt och med hög kvalitet. Med en ökande projektportfölj och många projekt i en mycket aktiv slutfas har Iconovo tillsatt två nya positioner som kommer bidra till ökad kapacitet i arbetet med såväl nya som existerande projekt.

Nina Bladh, Ph.D., har utsetts till Director Project Management. Nina har 25 års erfarenhet av utveckling av farmaceutiska produkter och kommer senast från en roll som Director CMC Regulatory Affairs på Camurus med stor erfarenhet av att ta farmaceutiska kombinationsprodukter hela vägen till marknad. Nina var dessförinnan på AstraZeneca i 16 år med bl.a. projektledande roller och arbete med inhalationsprodukter. Hon doktorerade 1995 i fysikalisk-organisk kemi vid Lunds Universitet. Nina kommer att ansvara för projektledningen av kundprojekt såväl som interna utvecklingsprojekt.

Måns Österberg Widerstrand har utsetts till Director Alliance Management. Måns har en bred erfarenhet från läkemedelsbranschen. Han började sin karriär som läkemedelsforskare, ledde senare produktion och R&D avdelningar men har de senaste 11 åren haft rådgivande och kundvårdande roller gentemot ledande läkare och B2B kunder, bl.a. som Key Account Manager på Thermo Fisher och Head of Global Generics Sales på Polypeptide. Senast kommer Måns från en roll som Senior Scientific Advisor Allergy på Thermo Fischer. Måns kommer att ansvara för kundvården gentemot befintliga kunder, följa projekten till marknad samt utveckla affären gentemot befintliga kunder. Han kommer ge en generell förstärkning av den kommersiella förmågan hos Iconovo.

”Vi kan idag meddela att vi tillsatt två viktiga nya positioner. Nina och Måns kommer med stor erfarenhet som är både direkt tillämplig och även komplementär till den kompetens som finns inom Iconovo i dag. Stärkta satsar vi nu framåt för att ta de existerande projekten till slutleverans. Vi kommer med de nya positionerna kunna intensifiera vår kommersiella ansats och arbeta vidare målmedvetet med att säkra fler kundkontrakt”, säger Johan Wäborg, VD för Iconovo.  

Iconovo announces two new recruitments to increase focus on customers’ needs and to deliver their projects in an effective and high-quality manner. With a growing project portfolio and many projects in a very active late phase, Iconovo has made appointments to two new positions that will contribute to an increased capacity for delivering new as well as existing projects.

Iconovo has accordingly appointed the following two new Directors.

Nina Bladh, PhD; has been appointed to Director Project Management. Nina has 25 years of experience in the development of pharmaceutical products. Her previous position was Director CMC Regulatory Affairs at Camurus, Lund, where she has gained considerable experience in taking pharmaceutical combination products to registration and launch. Prior to Camurus, Nina worked 16 years at AstraZenca including project management positions and work with inhalation products. She obtained her PhD in Physical Organic Chemistry at the University of Lund in 1995. Nina will primarily be responsible for leading customer and internal development projects.

Måns Österberg Widerstrand has been appointed to Director Alliance Management. Måns has a broad experience from the pharmaceutical industry. He started his career as a pharmaceutical scientist, later to lead manufacturing and R&D departments while the latest 11 years has been spent in advisory and customer relation roles with KOLs and B2B customers, such as Key Account Manager at Thermo Fisher and Head of Global Generics Sales at Polypeptide. Most recently, Måns held a position as Senior Scientific Advisor Allergy at Thermo Fischer. Måns will be responsible for the alliance management of current customers, follow our projects to market, while developing the business relationship with the customer. He brings a general strengthening of the commercial abilities of Iconovo.

”With joy I can today announce that we have appointed two persons in two newly created key positions. Nina and Måns brings a lot of experience that is directly applicable and complementary to the competence we have in Iconovo today. This is an important investment at a time when we move our existing projects towards final delivery. With these new positions we can intensify our commercial efforts and goal-oriented continue to secure new contracts with customers”, says Johan Wäborg, CEO at Iconovo.

Mats Johansson, styrelseordförande och den störste enskilde ägaren i Iconovo AB (publ), har förvärvat 5 000 aktier i bolaget för snittkurs 62,5 SEK per aktie. Efter förvärvet uppgår Mats Johanssons innehav till 925 000 aktier som ägs både privat och via bolag. Innehavet motsvarar 11,9% av aktierna i bolaget. 

Utöver Penser Bank följer även Danske Bank Iconovo. För att ta del av analysen använd denna länk, https://iconovo.se/investors/aktien/analys/